AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Cel-Sci Corporation
XASE · usd
SIC 2836 · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
FIGI BBG001SBRBG1
1.64▲ 0.03 (1.86%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
—
EV / Revenue
—
EV / EBITDA
Financial Highlights
Revenue (TTM)
—
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
—
Net Debt
Trading Information
Previous Close
1.61
Day's Range
1.57 – 1.64
52-Week Range
0.89 – 9.35
Volume
41.6K
Avg Volume
229.7K
Share Statistics
Shares Outstanding
Employees
44
Exchange
XASE
Listed
1983-12-08
Share count as of August 10, 2026

Cel-Sci Corporation (CVM) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Cel-Sci Corporation (CVM)
What is Cel-Sci Corporation's Market Cap?
Cel-Sci Corporation's Market Cap is $28.8M, based on as-reported figures from SEC (XBRL) filings.
What is Cel-Sci Corporation's Enterprise Value?
Cel-Sci Corporation's Enterprise Value is $32.8M, based on as-reported figures from SEC (XBRL) filings.
What is Cel-Sci Corporation's EV / EBITDA?
Cel-Sci Corporation's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Cel-Sci Corporation's Net Income (TTM)?
Cel-Sci Corporation's Net Income (TTM) is -$22.7M, based on as-reported figures from SEC (XBRL) filings.
What is Cel-Sci Corporation's EBITDA?
Cel-Sci Corporation's EBITDA is -$18.5M, based on as-reported figures from SEC (XBRL) filings.
What is Cel-Sci Corporation's Diluted EPS (TTM)?
Cel-Sci Corporation's Diluted EPS (TTM) is -1.29, based on as-reported figures from SEC (XBRL) filings.
What is Cel-Sci Corporation's Net Debt?
Cel-Sci Corporation's Net Debt is $3.9M, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · CVMAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Operating expenses:
Research and Development Expense
Selling, General and Administrative Expense
Total operating expenses
Operating loss
Net Interest Income
Non-Operating Income (Expense)
Net loss
Net loss available to common shareholders
Earnings Per Share (Diluted)